Du är här


Novartis International AG: Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH

Novartis International AG / Novartis Foundation healthcare models and disease
elimination programs showcasedat ECTMIH . Processed and transmitted by NASDAQ
OMX Corporate Solutions.The issuer is solely responsible for the content of
this announcement.
* Telemedicine pilot in rural Ghana demonstrated positive impact and improved
primary health services as reported by nurses, midwives and patients
* Retrospective contact tracing of former leprosy patients in Cambodia was
effective in reducing disability of new patients through earlier diagnosis
* Electronic supportive supervision of healthcare professionals in Tanzania
helped to identify major quality gaps and showed quick improvements in
* First mobile phone-facilitated leprosy detection system helps identify
patients in remote areas of the Philippines

Basel, September 7, 2015
The Novartis Foundation and its partners will highlight progress towards
transforming the health of the poorest populations at the 9thEuropean
Congress on Tropical Medicine and International Health (ECTMIH) held in Basel
from September 6 - 10. Updates on nine Novartis Foundation-sponsored
healthcare delivery models and disease elimination programs in low- and
middle-income countries will be showcased in scientific sessions and

"The ECTMIH is a great opportunity to join with our partners and the global
health community to review the progress we are making in the innovation of
healthcare delivery and disease elimination. It's an exciting time for us as
we are seeing projects such as Telemedicine in Ghana move towards scale and
integration into the local health system as well as new projects, such as our
leprosy contact tracing strategy, begin to gain momentum," said Dr. Ann
Aerts, Head of the Novartis Foundation.

Novartis Foundation-sponsored projects presented at ECTMIH scientific

* Identifying and addressing structural gaps in primary health care in
Tanzania (Abstract 1390, September 7, 15:30 CET)
* Ghana telemedicine - using mHealth to bridge the gaps in health service and
availability and accessibility (Abstract 218, September 8, 15:30 CET)
* Cambodia retrospective contact tracing project: innovation in contact
tracing to improve early diagnosis of leprosy (Abstract 773, September 9,
10:30 CET)
* Leprosy alert response network and surveillance system (LEARNS): Iloilo
implementation (Abstract 570, September 9, 10:30 CET)
* Evaluation of a community based program for hypertension control in Ghana
(Abstract 610, September 9, 12:15 CET)
* Public-private partnerships to strengthen human resources for health
through training and eLearning: a case study from Tanzania (Abstract 1018,
September 9, 12:15)

Novartis-sponsored symposia at ECTMIH

* On the road to malaria elimination: where we have come from and what
challenges lie ahead? (September 7, 12:00) Co-sponsored by the Novartis
Malaria Initiative, the Novartis Institute for Tropical Disease and the
Novartis Foundation
* Digital Health on the Ground (September 8, 17:00) Sponsored by the Novartis

Added Ann Aerts, "Our objective at ECTMIH is to share our learnings, the
successes and challenges, with the global health community and in turn, learn
as much as we can from them for our own work. We need to be open and
collaborative as we are all aiming towards the same goal to transform the
health of the poorest populations."

About the Novartis Foundation

The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of
the poorest populations. We work hand-in-hand with our local and global
partners to catalyze scalable and sustainable healthcare models to improve
access and health outcomes, and to accelerate efforts to eliminate leprosy
and malaria by focusing on interventions that aim to interrupt transmission.
Everything we do is grounded in evidence and innovation, and our work is a
continuous cycle of evaluation, adaptation and application. In 2014, the
operational budget for the foundation was CHF 12 million and our programs
reached 3.6 million people.

For more information, please visit:


Novartis Foundation is on Twitter. Sign up to follow @NovartisFDN

Novartis Tropical Disease

Novartis is committed to combatting tropical diseases such as malaria, dengue
fever and leprosy, which continue to have a devastating effect on millions of
people living in under privileged areas of the world. We do this with
innovative research at the Novartis Institute for Tropical Diseases (NITD) in
Singapore, where our scientists use the latest techniques to discover next
generation treatments for some of these conditions. At the same time, we are
working to control and eliminate these diseases by improving access to
treatments through our Malaria Initiative and pioneering innovative
healthcare models through the Novartis Foundation. Since 2001, the Malaria
Initiative has delivered more than 700 million antimalarial treatments to
patients without profit, contributing to a significant reduction of the death
toll from malaria. The Novartis Foundation works to accelerate efforts to
eliminate leprosy and malaria by focusing on interventions that aim to
interrupt transmission. Novartis has also worked with the World Health
Organization (WHO) to provide free multidrug therapy (MDT) to leprosy
patients globally since 2000. Learn more about our efforts


This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "pilot,"
"will," "opportunity," "exciting," "move towards," "strategy," "begin,"
"objective," "aiming," "goal," "can," "focusing on," "aim," "continuous,"
"committed," "continue," "working to," "pioneering," "works to," "efforts,"
or similar expressions. Such forward-looking statements reflect the current
views of the Group regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results expressed or implied by such
statements. These expectations could be affected by, among other things,
risks and factors referred to in the Risk Factors section of Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update it in the future.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2014, the Group
achieved net sales of USD 58.0 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 120,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

# # #

Novartis Media Relations

| Central media line : |
|+41 61 324 2200 |
| Eric Althoff Julie Morrow |
| |
|Novartis Global Media Relations Novartis Foundation |
|+41 61 324 7999 (direct) +41 61 696 2421 (direct) |
|+41 79 593 4202 (mobile) +41 79 224 5666 (mobile) |
|eric.althoff@novartis.com julie.morrow@novartis.com |
e-mail: media.relations@novartis.com

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please

Novartis Investor Relations

| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.